156 related articles for article (PubMed ID: 15943892)
1. Role of epidermal growth factor receptor mutations in predicting sensitivity or resistance to targeted agents in non-small-cell lung cancer.
Reddy GK
Clin Lung Cancer; 2005 May; 6(6):338-9. PubMed ID: 15943892
[No Abstract] [Full Text] [Related]
2. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
Kobayashi S; Boggon TJ; Dayaram T; Jänne PA; Kocher O; Meyerson M; Johnson BE; Eck MJ; Tenen DG; Halmos B
N Engl J Med; 2005 Feb; 352(8):786-92. PubMed ID: 15728811
[TBL] [Abstract][Full Text] [Related]
3. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Lynch TJ; Bell DW; Sordella R; Gurubhagavatula S; Okimoto RA; Brannigan BW; Harris PL; Haserlat SM; Supko JG; Haluska FG; Louis DN; Christiani DC; Settleman J; Haber DA
N Engl J Med; 2004 May; 350(21):2129-39. PubMed ID: 15118073
[TBL] [Abstract][Full Text] [Related]
4. Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer.
Clin Lung Cancer; 2004 May; 5(6):331-2. PubMed ID: 15217530
[No Abstract] [Full Text] [Related]
5. EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients.
Wang Z; Wu YL; Zhang GC; Zhou Q; Xu CR; Guo AL
Onkologie; 2008 Apr; 31(4):174-8. PubMed ID: 18418018
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.
Bai H; Mao L; Wang HS; Zhao J; Yang L; An TT; Wang X; Duan CJ; Wu NM; Guo ZQ; Liu YX; Liu HN; Wang YY; Wang J
J Clin Oncol; 2009 Jun; 27(16):2653-9. PubMed ID: 19414683
[TBL] [Abstract][Full Text] [Related]
7. Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.
Costa DB; Schumer ST; Tenen DG; Kobayashi S
J Clin Oncol; 2008 Mar; 26(7):1182-4; author reply 1184-6. PubMed ID: 18309959
[No Abstract] [Full Text] [Related]
8. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.
Taron M; Ichinose Y; Rosell R; Mok T; Massuti B; Zamora L; Mate JL; Manegold C; Ono M; Queralt C; Jahan T; Sanchez JJ; Sanchez-Ronco M; Hsue V; Jablons D; Sanchez JM; Moran T
Clin Cancer Res; 2005 Aug; 11(16):5878-85. PubMed ID: 16115929
[TBL] [Abstract][Full Text] [Related]
9. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Takezawa K; Okamoto I; Tanizaki J; Kuwata K; Yamaguchi H; Fukuoka M; Nishio K; Nakagawa K
Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow.
Dancey JE
Cancer Cell; 2004 May; 5(5):411-5. PubMed ID: 15144948
[TBL] [Abstract][Full Text] [Related]
11. Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
Stinchcombe TE; Ramalingam SS
Lancet Oncol; 2010 Jun; 11(6):500-1. PubMed ID: 20493770
[No Abstract] [Full Text] [Related]
12. Histoculture drug response assay for gefitinib in non-small-cell lung cancer.
Yoshimasu T; Ohta F; Oura S; Tamaki T; Shimizu Y; Naito K; Kiyoi M; Hirai Y; Kawago M; Okamura Y
Gen Thorac Cardiovasc Surg; 2009 Mar; 57(3):138-43. PubMed ID: 19280309
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA).
Kimura H; Suminoe M; Kasahara K; Sone T; Araya T; Tamori S; Koizumi F; Nishio K; Miyamoto K; Fujimura M; Nakao S
Br J Cancer; 2007 Sep; 97(6):778-84. PubMed ID: 17848912
[TBL] [Abstract][Full Text] [Related]
14. Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial.
Price N; Belani C
Clin Lung Cancer; 2005 Jan; 6(4):214-6. PubMed ID: 15694012
[No Abstract] [Full Text] [Related]
15. Clinical aspects of epidermal growth factor receptor inhibitors: benefit and risk.
Kato T; Nishio K
Respirology; 2006 Nov; 11(6):693-8. PubMed ID: 17052296
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy.
Saijo N
Nat Rev Clin Oncol; 2010 Nov; 7(11):618-9. PubMed ID: 20981125
[No Abstract] [Full Text] [Related]
17. The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib.
Nie Q; Wang Z; Zhang GC; An SJ; Lin JY; Guo AL; Li R; Gan B; Huang Y; Mok TS; Wu YL
Eur J Pharmacol; 2007 Sep; 570(1-3):175-81. PubMed ID: 17597605
[TBL] [Abstract][Full Text] [Related]
18. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Paez JG; Jänne PA; Lee JC; Tracy S; Greulich H; Gabriel S; Herman P; Kaye FJ; Lindeman N; Boggon TJ; Naoki K; Sasaki H; Fujii Y; Eck MJ; Sellers WR; Johnson BE; Meyerson M
Science; 2004 Jun; 304(5676):1497-500. PubMed ID: 15118125
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).
Martínez-Navarro EM; Rebollo J; González-Manzano R; Sureda M; Evgenyeva E; Valenzuela B; Fernández FJ; Forteza J; Brugarolas A
Clin Transl Oncol; 2011 Nov; 13(11):812-8. PubMed ID: 22082647
[TBL] [Abstract][Full Text] [Related]
20. [Correlation of epidermal growth factor receptor mutations and HER2/3 protein expression with clinical outcome in advanced non-small cell lung cancer patients treated with gefitinib].
Han Y; Xu JM; Duan HQ; Zhang Y; Liu XQ; Zhang JS
Chin J Cancer; 2010 Jan; 29(1):69-75. PubMed ID: 20038315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]